Skip to main content
Top
Published in: Hepatology International 4/2017

01-07-2017 | Editorial

Extracorporeal devices for treatment of refractory pruritus in cholestatic liver disease

Author: Roger Williams

Published in: Hepatology International | Issue 4/2017

Login to get access

Excerpt

An invitation to write an editorial around the paper entitled “Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease” was just too much for me to resist. Since the 1970s and our early work on hemoperfusion for temporary liver support in fulminant hepatic failure, I have had a passionate belief in the value of charcoal and other adsorbents for removal of protein-bound toxic substances [1]. Intractable pruritus defines failure of control by the well-tried sequential regime of bile acid sequestrant (cholestyramine or colesevelam), enzyme-inducing agent (rifampicin), opioid antagonist (naltrexone), and selective serotonin inhibitor (sertraline). It affects a relatively small group of patients with primary biliary cholangitis (PBC), 3–5% only. Nevertheless, for these patients, pruritus can be disabling with poor quality of life, sleep deprivation, and even suicidal ideation. The cause of the severe pruritus has long been a puzzle, as there is no correlation with the severity of the underlying disease. Liver structure and function are often well preserved in these patients, making transplantation—which is the last resort in treatment—difficult to justify. …
Literature
1.
go back to reference Gazzard BG, Weston MJ, Murray-Lyon IM, Flax H, Record CO, Williams R, Portmann B, Langley PG, Dunlop EH, Mellon PJ, Ward MB. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet. 1974;1:1301–7.CrossRefPubMed Gazzard BG, Weston MJ, Murray-Lyon IM, Flax H, Record CO, Williams R, Portmann B, Langley PG, Dunlop EH, Mellon PJ, Ward MB. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet. 1974;1:1301–7.CrossRefPubMed
2.
go back to reference Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, Watt KD, Cramer CH, Leung N. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int. 2016. doi:10.1007/s12072-016-9775-9. Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, Watt KD, Cramer CH, Leung N. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int. 2016. doi:10.​1007/​s12072-016-9775-9.
3.
go back to reference Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Burgstaler EA, Carlson GL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet. 1980;2:53–5.CrossRefPubMed Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Burgstaler EA, Carlson GL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet. 1980;2:53–5.CrossRefPubMed
4.
go back to reference Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;2010(53):307–12.CrossRef Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;2010(53):307–12.CrossRef
5.
go back to reference Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther. 2012;2012(35):696–704.CrossRef Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther. 2012;2012(35):696–704.CrossRef
6.
go back to reference Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, van Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Oude Elferink RP, Beuers U. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;2012(56):1391–400.CrossRef Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, van Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Oude Elferink RP, Beuers U. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;2012(56):1391–400.CrossRef
7.
go back to reference Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008–18.CrossRefPubMed Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008–18.CrossRefPubMed
8.
go back to reference Oude Elferink RP, Kremer AE, Martens JJ, Beuers UH. The molecular mechanism of cholestatic pruritus. Dig Dis. 2011;2011(29):66–71.CrossRef Oude Elferink RP, Kremer AE, Martens JJ, Beuers UH. The molecular mechanism of cholestatic pruritus. Dig Dis. 2011;2011(29):66–71.CrossRef
9.
go back to reference Krawczyk M, Liebe R, Wasilewicz M, Wunsch E, Raszeja-Wyszomirska J, Milkiewicz P. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. Liver Int. 2017;37:743–47. doi:10.1111/liv.13281.CrossRefPubMed Krawczyk M, Liebe R, Wasilewicz M, Wunsch E, Raszeja-Wyszomirska J, Milkiewicz P. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. Liver Int. 2017;37:743–47. doi:10.​1111/​liv.​13281.CrossRefPubMed
10.
go back to reference Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EM, van Buuren HR, Lammert F, Corpechot C, Jones DE. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016;2016(43):294–302.CrossRef Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EM, van Buuren HR, Lammert F, Corpechot C, Jones DE. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016;2016(43):294–302.CrossRef
11.
go back to reference Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114–23.CrossRefPubMed Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114–23.CrossRefPubMed
12.
go back to reference Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis. 2015;2015(33):164–75.CrossRef Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis. 2015;2015(33):164–75.CrossRef
Metadata
Title
Extracorporeal devices for treatment of refractory pruritus in cholestatic liver disease
Author
Roger Williams
Publication date
01-07-2017
Publisher
Springer India
Published in
Hepatology International / Issue 4/2017
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-017-9802-5

Other articles of this Issue 4/2017

Hepatology International 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.